Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk
Date
2002-10Author
Farquhar, C
VanCott, TC
Mbori-Ngacha, DA
Horani, L
Bosire, RK
Kreiss, JK
Richardson, BA
John-Stewart, GC
Type
ArticleLanguage
enMetadata
Show full item recordAbstract
Secretory leukocyte protease inhibitor (SLPI), a protein found in saliva, breast milk, and genital secretions, is capable of inhibiting human immunodeficiency virus (HIV) type 1 in vitro. The aim of this study was to determine whether SLPI in infant saliva provides protection against mother-to-child HIV-1 transmission. In total, 602 saliva specimens were collected from 188 infants at birth and at ages 1, 3, and 6 months. Infants' median salivary SLPI concentrations were higher at birth than at 6 months (341 vs. 219 ng/mL; P=.001). There was no association between SLPI concentration and HIV-1 transmission overall. However, among 122 breast-fed infants who were HIV-1 uninfected at 1 month, higher salivary SLPI levels were associated with a decreased risk of HIV-1 transmission through breast milk (hazard ratio, 0.5; 95% confidence interval, 0.3-0.9; P=.03). These results suggest that SLPI plays an important role in reducing HIV-1 transmission through breast milk.
URI
http://www.ncbi.nlm.nih.gov/pubmed/18505437http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/30384
Citation
J Infect Dis. 2002 Oct 15;186(8):1173-6. Epub 2002 Sep 20.Publisher
University of Nairobi. Department of Paediatrics and Child Health, Univeristy of Nairobi, Kenya
Collections
- Faculty of Health Sciences (FHS) [10377]